Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate

ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging coronavirus infecting humans that is associated with acute pneumonia, occasional renal failure, and a high mortality rate and is considered a threat to public health. The construction of a full-length infectious cDNA clone of the MERS-CoV genome in a bacterial artificial chromosome is reported here, providing a reverse genetics system to study the molecular biology of the virus and to develop attenuated viruses as vaccine candidates. Following transfection with the cDNA clone, infectious virus was rescued in both Vero A66 and Huh-7 cells. Recombinant MERS-CoVs (rMERS-CoVs) lacking the accessory genes 3, 4a, 4b, and 5 were successfully rescued from cDNA clones with these genes deleted. The mutant viruses presented growth kinetics similar to those of the wild-type virus, indicating that accessory genes were not essential for MERS-CoV replication in cell cultures. In contrast, an engineered mutant virus lacking the structural E protein (rMERS-CoV-ΔE) was not successfully rescued, since viral infectivity was lost at early passages. Interestingly, the rMERS-CoV-ΔE genome replicated after cDNA clone was transfected into cells. The infectious virus was rescued and propagated in cells expressing the E protein in trans, indicating that this virus was replication competent and propagation defective. Therefore, the rMERS-CoV-ΔE mutant virus is potentially a safe and promising vaccine candidate to prevent MERS-CoV infection. IMPORTANCE Since the emergence of MERS-CoV in the Arabian Peninsula during the summer of 2012, it has already spread to 10 different countries, infecting around 94 persons and showing a mortality rate higher than 50%. This article describes the development of the first reverse genetics system for MERS-CoV, based on the construction of an infectious cDNA clone inserted into a bacterial artificial chromosome. Using this system, a collection of rMERS-CoV deletion mutants has been generated. Interestingly, one of the mutants with the E gene deleted was a replication-competent, propagation-defective virus that could only be grown in the laboratory by providing E protein in trans, whereas it would only survive a single virus infection cycle in vivo. This virus constitutes a vaccine candidate that may represent a balance between safety and efficacy for the induction of mucosal immunity, which is needed to prevent MERS-CoV infection. Since the emergence of MERS-CoV in the Arabian Peninsula during the summer of 2012, it has already spread to 10 different countries, infecting around 94 persons and showing a mortality rate higher than 50%. This article describes the development of the first reverse genetics system for MERS-CoV, based on the construction of an infectious cDNA clone inserted into a bacterial artificial chromosome. Using this system, a collection of rMERS-CoV deletion mutants has been generated. Interestingly, one of the mutants with the E gene deleted was a replication-competent, propagation-defective virus that could only be grown in the laboratory by providing E protein in trans, whereas it would only survive a single virus infection cycle in vivo. This virus constitutes a vaccine candidate that may represent a balance between safety and efficacy for the induction of mucosal immunity, which is needed to prevent MERS-CoV infection.

[1]  T. Bestebroer,et al.  MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment , 2013, The Journal of general virology.

[2]  D. Cummings,et al.  Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.

[3]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[4]  Juan Carlos Oliveros,et al.  Alphacoronavirus Protein 7 Modulates Host Innate Immune Response , 2013, Journal of Virology.

[5]  Lu Lu,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread , 2013, Microbes and Infection.

[6]  B. Bosch,et al.  The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies , 2013, Journal of Virology.

[7]  Victor M Corman,et al.  Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection , 2013, The Lancet Infectious Diseases.

[8]  P. Gastañaduy Update: Severe Respiratory Illness Associated With Middle East Respiratory Syndrome Coronavirus (MERS-CoV)—Worldwide, 2012–2013 , 2013, American Journal of Transplantation.

[9]  Clio,et al.  First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  A. Fontanet,et al.  Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission , 2013, The Lancet.

[11]  Christian Drosten,et al.  Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group , 2013, Journal of Virology.

[12]  Y. Guan,et al.  Full-Genome Deep Sequencing and Phylogenetic Analysis of Novel Human Betacoronavirus , 2013, Emerging infectious diseases.

[13]  H. Feldmann,et al.  Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin , 2013, Scientific Reports.

[14]  H. Feldmann,et al.  Pneumonia from human coronavirus in a macaque model. , 2013, The New England journal of medicine.

[15]  S. Perlman,et al.  Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.

[16]  Y. Guan,et al.  Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures , 2013, Journal of Virology.

[17]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[18]  Chantal Reusken,et al.  Human Betacoronavirus 2c EMC/2012–related Viruses in Bats, Ghana and Europe , 2013, Emerging infectious diseases.

[19]  Markus Eickmann,et al.  Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[20]  B. Sibal,et al.  Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[21]  Alexander E. Gorbalenya,et al.  Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans , 2012, mBio.

[22]  R. Baric,et al.  A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease , 2012, Nature Medicine.

[23]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[24]  M. Catchpole,et al.  Novel coronavirus associated with severe respiratory disease: case definition and public health measures. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[25]  T. Bestebroer,et al.  Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[26]  L. Enjuanes,et al.  Molecular Characterization of Feline Infectious Peritonitis Virus Strain DF-2 and Studies of the Role of ORF3abc in Viral Cell Tropism , 2012, Journal of Virology.

[27]  F. Pozo,et al.  Detection of alpha and betacoronaviruses in multiple Iberian bat species , 2011, Archives of Virology.

[28]  N. Van Rooijen,et al.  Cell-Type-Specific Type I Interferon Antagonism Influences Organ Tropism of Murine Coronavirus , 2011, Journal of Virology.

[29]  I. Sola,et al.  Coronavirus Gene 7 Counteracts Host Defenses and Modulates Virus Virulence , 2011, PLoS pathogens.

[30]  S. Goebel,et al.  Accessory Protein 5a Is a Major Antagonist of the Antiviral Action of Interferon against Murine Coronavirus , 2010, Journal of Virology.

[31]  Jincun Zhao,et al.  Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease , 2010, Virology.

[32]  S. Perlman,et al.  Coronaviruses post-SARS: update on replication and pathogenesis , 2009, Nature Reviews Microbiology.

[33]  R. Johnston,et al.  Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice , 2008, Proceedings of the National Academy of Sciences.

[34]  R. Baric,et al.  A Live Attenuated Severe Acute Respiratory Syndrome Coronavirus Is Immunogenic and Efficacious in Golden Syrian Hamsters , 2008, Journal of Virology.

[35]  S. Perlman,et al.  Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice , 2008, Virology.

[36]  Krishna Shankara Narayanan,et al.  Severe Acute Respiratory Syndrome Coronavirus nsp1 Suppresses Host Gene Expression, Including That of Type I Interferon, in Infected Cells , 2008, Journal of Virology.

[37]  C. Peters,et al.  Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV , 2007, Vaccine.

[38]  R. Baric,et al.  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease , 2007, Virus Research.

[39]  Jianjun Chen,et al.  Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice , 2007, Immunology.

[40]  R. Baric,et al.  Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain , 2007, Journal of Virology.

[41]  L. Enjuanes,et al.  Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway , 2007, Virology.

[42]  P. Woo,et al.  Comparative Analysis of Twelve Genomes of Three Novel Group 2c and Group 2d Coronaviruses Reveals Unique Group and Subgroup Features , 2006, Journal of Virology.

[43]  P. Palese,et al.  Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists , 2006, Journal of Virology.

[44]  K. Subbarao,et al.  A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In Vivo , 2006, Journal of Virology.

[45]  S. Alonso,et al.  Construction of a Severe Acute Respiratory Syndrome Coronavirus Infectious cDNA Clone and a Replicon To Study Coronavirus RNA Synthesis , 2006, Journal of Virology.

[46]  L. Enjuanes,et al.  Recovery of a Neurovirulent Human Coronavirus OC43 from an Infectious cDNA Clone , 2006, Journal of Virology.

[47]  R. Brunham,et al.  Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. , 2006, The Journal of general virology.

[48]  Y. Zhang,et al.  Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine , 2005, Vaccine.

[49]  M. Reiter,et al.  A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses , 2005, Vaccine.

[50]  R. Baric,et al.  Severe Acute Respiratory Syndrome Coronavirus Group-Specific Open Reading Frames Encode Nonessential Functions for Replication in Cell Cultures and Mice , 2005, Journal of Virology.

[51]  L. Wen,et al.  Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys , 2005, Vaccine.

[52]  L. Enjuanes,et al.  The Nucleoprotein Is Required for Efficient Coronavirus Genome Replication , 2004, Journal of Virology.

[53]  Lili Kuo,et al.  The Small Envelope Protein E Is Not Essential for Murine Coronavirus Replication , 2003, Journal of Virology.

[54]  S. Alonso,et al.  Engineering the Transmissible Gastroenteritis Virus Genome as an Expression Vector Inducing Lactogenic Immunity , 2003, Journal of Virology.

[55]  I. Sola,et al.  Transmissible gastroenteritis coronavirus gene 7 is not essential but influences in vivo virus replication and virulence , 2003, Virology.

[56]  P. Rottier,et al.  Coronaviruses Maintain Viability despite Dramatic Rearrangements of the Strictly Conserved Genome Organization , 2002, Journal of Virology.

[57]  Javier Ortego,et al.  Generation of a Replication-Competent, Propagation-Deficient Virus Vector Based on the Transmissible Gastroenteritis Coronavirus Genome , 2002, Journal of Virology.

[58]  P. Rottier,et al.  The Group-Specific Murine Coronavirus Genes Are Not Essential, but Their Deletion, by Reverse Genetics, Is Attenuating in the Natural Host , 2002, Virology.

[59]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[60]  J. M. González,et al.  Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. An,et al.  Induction of Apoptosis in Murine Coronavirus-Infected Cultured Cells and Demonstration of E Protein as an Apoptosis Inducer , 1999, Journal of Virology.

[62]  K. Wang,et al.  Complete nucleotide sequence of two generations of a bacterial artificial chromosome cloning vector. , 1997, BioTechniques.

[63]  B. Birren,et al.  Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. , 1992, Proceedings of the National Academy of Sciences of the United States of America.